Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.PH)

ZIOP.PH on Philadelphia Stock Exchange

6.10USD
21 Jul 2017
Change (% chg)

-- (--)
Prev Close
$6.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,958
52-wk High
$7.87
52-wk Low
$4.47

ZIOP.PH

Chart for ZIOP.PH

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $866.75
Shares Outstanding(Mil.): 142.09
Dividend: --
Yield (%): --

Financials

  ZIOP.PH Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -1.38 -- --
ROI: -167.56 -7.93 -8.31
ROE: -- -9.29 -7.95

BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

* Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

Jun 28 2017

BRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology

* CVI Investments Inc reports a 6.8 percent passive stake in Ziopharm Oncology Inc as of May 11, 2017 - sec filing Source text - http://bit.ly/2q42eo3 Further company coverage:

May 22 2017

BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy

* Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia

May 02 2017

BRIEF-Ziopharm Oncology reports Q1 loss per share $0.15

* Ziopharm Oncology reports first quarter 2017 financial results and provides update on recent activities

May 01 2017

BRIEF-Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications

* Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications Source text for Eikon: Further company coverage:

Mar 27 2017

BRIEF-Ziopharm Q4 loss per share $0.11

* Ziopharm reports fourth-quarter 2016 financial results and provides update on recent activities

Feb 16 2017

Earnings vs. Estimates